King & Spalding’s Thomas “Tom” Duley has forged his place as a go-to lawyer in the life sciences, particularly for biotech and pharmaceutical companies looking to hash out cooperation agreements to get cutting-edge products to market. This past year, it was SciClone Pharmaceuticals Inc. in an exclusive licensing deal with Soligenix Inc. to develop, promote and market an oral mucositis treatment in patients with head and neck cancer in China, Taiwan, South Korea and Vietnam. Duley told The Recorder about the past year’s highlights, how he developed his unique practice and his approach to client service.
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org